TriangleNCT01154452 · OUTCOME
Response Rate (CR + PR) as Assessed by RECIST 1.1 (Phase Ib and II)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 4 months
What was measured
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions
Groups in this outcome
RO4929097 10mg
RO4929097: 10mg PO QD, GDC-0449: 150 mg PO QD
RO4929097 15 mg
RO4929097: 15 mg PO QD, GDC-0449: 150 mg PO QD
ARM 1 - RO4929097: 15 mg PO QD
ARM 1 - RO4929097: 15 mg PO QD
ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD
ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD
| Group | Source count |
|---|---|
| RO4929097 10mg | 3 |
| RO4929097 15 mg | 3 |
| ARM 1 - RO4929097: 15 mg PO QD | 30 |
| ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD | 27 |
Reported measurements
Stable Disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| RO4929097 10mg | 2 | Not reported | Not reported | Not reported | Not reported |
| RO4929097 15 mg | 2 | Not reported | Not reported | Not reported | Not reported |
| ARM 1 - RO4929097: 15 mg PO QD | 17 | Not reported | Not reported | Not reported | Not reported |
| ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD | 16 | Not reported | Not reported | Not reported | Not reported |
Progression of Disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| RO4929097 10mg | 1 | Not reported | Not reported | Not reported | Not reported |
| RO4929097 15 mg | 1 | Not reported | Not reported | Not reported | Not reported |
| ARM 1 - RO4929097: 15 mg PO QD | 13 | Not reported | Not reported | Not reported | Not reported |
| ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD | 11 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 17
- group Id
- OG003
- value
- 16
- title
- Stable Disease
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 13
- group Id
- OG003
- value
- 11
- title
- Progression of Disease
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 30
- group Id
- OG003
- value
- 27
- units
- Participants
- description
- Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions
- groups
- description
- RO4929097: 10mg PO QD, GDC-0449: 150 mg PO QD
- id
- OG000
- title
- RO4929097 10mg
- description
- RO4929097: 15 mg PO QD, GDC-0449: 150 mg PO QD
- id
- OG001
- title
- RO4929097 15 mg
- description
- ARM 1 - RO4929097: 15 mg PO QD
- id
- OG002
- title
- ARM 1 - RO4929097: 15 mg PO QD
- description
- ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD
- id
- OG003
- title
- ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- Up to 4 months
- title
- Response Rate (CR + PR) as Assessed by RECIST 1.1 (Phase Ib and II)
- type
- SECONDARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice